

*The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) takes no responsibility for the contents of this announcement, makes no representation as to its accuracy and completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**VENTUREPHARM LABORATORIES LIMITED**  
**萬全科技藥業有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code:8225)**

**(the “Company”)**

**CHANGE OF COMPANY SECRETARY AND  
AUTHORISED REPRESENTATIVE OF THE COMPANY**

The board of directors of the Company (the “Board”) hereby announces that Mr. Leung Kwok Fai Ben Rich (“Mr. Leung”) has been appointed as the Company Secretary and Authorized Representative of the Company with effect from 17 September 2009. Ms. Ning Ding (“Ms. Ning”) has tendered her notice of resignation as Company Secretary and Authorized Representative with effect from 17 September 2009.

Ms. Ning has confirmed that she has no disagreement with the Board and there is no circumstance relating to her resignation that needs to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited. The Board would like to take this opportunity to express its appreciation to Ms. Ning for her contribution to the Company during her tenure.

Mr. Leung is a member of The Institute of Certified Public Accountants and The Hong Kong Institute of Chartered Secretaries for years. Mr. Leung has over 20 years of experiences in accounting and finance management. The Board consents the qualification of Mr. Leung in compliance with the Rule 5.14 and 5.15 of the GEM Listing Rules.

By order of the Board  
Venturepharm Laboratories Limited  
William Xia GUO  
Chairman

Beijing, the PRC, 17 September 2009

*As at the date of this announcement, the Board comprises two executive directors, being Mr. William Xia Guo and Dr. Maria Xue Mei Song; three non-executive directors, being Mr. Feng Tao, Mr. Wu Xin and Dr. Nathan Xin Zhang; and three independent non-executive directors, being Mr. Wang Hong Bo, Mr. Paul Contomichalos*

and Mr. Wu Ming Yu.

*This announcement, for which the directors of the Company (the “Directors”) collectively and individually accept responsibility, includes particulars given in compliance with the Rules Governing the Listing of securities of the Growth Enterprise Market of the Stock Exchange for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, conform that, to the best of their knowledge and belief: (1) the information contained in this announcement is accurate and complete in all material respect and not misleading; (2) there are no other matters the omission of which would make any statement in all material respects and not misleading; and (3) all opinions expressed in this announcement have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.*

*This announcement will remain on the GEM website with the domain name of [www.hkgem.com](http://www.hkgem.com) on the “Latest Company Announcements” page for at least 7days from the date of its posting and on the Company’s website at [www.venturepharm.com](http://www.venturepharm.com)*

*\* for identification purpose only*